interesting article, however posting an article that supports your point of view is standard confirmation bias. The clinical value of chemokine receptor antagonists is evident from the successful application of drugs like plerixafor, maraviroc, and mogamulizumab, which have shown therapeutic efficacy in their respective indications despite the issue of tolerance
And honestly, i dont understand the point. Just because something may become less effective overtime does that mean its not worth taking at all? The scientific advisory board would disagree
Dimerix (ASX: DXB) Discussion Thread, page-425
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
0.035(6.67%) |
Mkt cap ! $308.1M | |||
| Open | High | Low | Value | Volume |
| 51.5¢ | 57.3¢ | 50.5¢ | $2.179M | 3.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30558 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.5¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |